ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: FR-PO983

Dapagliflozin Suppresses Urinary Biomarkers of Kidney Damage Regardless of Proteinuric Levels in CKD

Session Information

Category: CKD (Non-Dialysis)

  • 2302 CKD (Non-Dialysis): Clinical, Outcomes, and Trials


  • Kim, Soyeon, Soonchunhyang University Hospital, Seoul, Korea (the Republic of)
  • Chu, Seung Hye, Soonchunhyang University Hospital, Seoul, Korea (the Republic of)
  • Noh, Hyunjin, Soonchunhyang University Hospital, Seoul, Korea (the Republic of)
  • Kwon, Soon hyo, Soonchunhyang University Hospital, Seoul, Korea (the Republic of)

Sodium glucose cotransporter 2 inhibitor (SGLT2i) reduce the risk of chronic kidney disease (CKD) progression in individuals with or without diabetes mellitus (DM). However, the beneficial effect of SGL2i on CKD patients with low levels of proteinuria has not been established. The objective of this study was to compare the effect of dapagliflozin on biomarkers of kidney injury in CKD patients stratified by albuminuria level.


We prospectively enrolled healthy volunteers (HVs) (n=20) and CKD patients (n=43) with or without DM. The CKD group received dapagliflozin (10mg). Urine and serum samples were collected before treatment and 3 and 6 months after administration of dapagliflozin. We measured kidney injury molecule-1 (KIM-1), interleukin-1β (IL-1β) and mitochondrial DNA nicotinamide adenine dinucleotide dehydrogenase subunit-1 (mtND1) copy number in the urine.


Age did not differ between HV and CKD patients (52.05 ± 8.13 vs 53.90 ± 14.96 years, p=0.774). The estimated glomerular filtration rate (eGFR) level of CKD patients was lower than that of HV (62.55 ± 24.22 vs 94.95 ± 11.21 mL/min, p < 0.001). Among the CKD patients, 11 % (n=5) had diabetes. The median urinary albumin/creatinine ratio (uACR) in CKD patients was 339.80 mg/g (IQR 80.0-647.0 mg/g). Kidney injury markers were significantly elevated in the CKD patients compared to the HVs. Dapagliflozin reduced urinary KIM-1, IL-1 β and mtND-1 in CKD at 6 months after treatment (p < 0.001, p < 0.001 and p = 0.021, respectively). Futhermore, when CKD patients were divided into two groups according to uACR level (< 300 mg/g, ≥ 300 mg/g), dapagliflozin decreased urinary KIM-1 and IL-1β at 3 months after treatment in the high albuminuria group (n=22) (p=0.034 and p=0.047, respectively). In the low albuminuria group (n=20), uKIM-1 and IL-1β decreased after 6 months of dapagliflozin treatment (p=0.004 and p=0.0021). However, dapagliflozin did not change uACR and eGFR during the study period.


CKD patients with high albuminuria showed an earlier response to dapagliflozin compared to those with low albuminuria. Nevertheless, dapagliflozin demonstrated a reduction in urinary kidney injury biomarkers in CKD patients regardless of proteinuria levels. These findings suggest that SGLT2i may attenuate the progression of low proteinuric CKD.


  • Government Support – Non-U.S.